Gabriel N. Hortobágyi

Top papers

• Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

  Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, et al.·2008·Journal of Clinical Oncology
  ↗ 2,885OA
• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

  José Baselga, Mario Campone, Martine Piccart, et al.·2011·New England Journal of Medicine
  ↗ 2,815OA
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

  Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, et al.·2016·New England Journal of Medicine
  ↗ 1,973OA
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  Roman Rouzier, Charles M. Perou, W. Fraser Symmans, et al.·2005·Clinical Cancer Research
  ↗ 1,882OA
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

  Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou, et al.·2004·Cancer Cell
  ↗ 1,859OA
• Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

  Benjamin D. Smith, Grace L. Smith, Arti Hurria, et al.·2009·Journal of Clinical Oncology
  ↗ 1,723OA
• Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

  W. Fraser Symmans, Florentia Peintinger, Christos Hatzis, et al.·2007·Journal of Clinical Oncology
  ↗ 1,642OA
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

  Kathy S. Albain, William E. Barlow, Steven Shak, et al.·2009·The Lancet Oncology
  ↗ 1,396OA
• Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

  Henry M. Kuerer, Lisa A. Newman, Terry L. Smith, et al.·1999·Journal of Clinical Oncology
  ↗ 1,336
• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

  Rashmi K. Murthy, Sherene Loi, Alicia Okines, et al.·2019·New England Journal of Medicine
  ↗ 1,290OA
• ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

  Weiyi Toy, Yang Shen, Helen Won, et al.·2013·Nature Genetics
  ↗ 1,242OA
• Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

  Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis, et al.·2005·Journal of Clinical Oncology
  ↗ 1,168OA